Cogent Biosciences (COGT) Amortization of Deferred Charges (2017 - 2026)

Cogent Biosciences (COGT) recorded quarterly Amortization of Deferred Charges of $278000.0 in Q1 2026, up 16.81% quarter-over-quarter from $238000.0 in Q4 2025.

Cogent Biosciences (COGT) Amortization of Deferred Charges (2017 - 2026) Analysis & Trends

Cogent Biosciences' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $278000.0 for Q1 2026.

  • In Q1 2026, Amortization of Deferred Charges changed N/A year-over-year to $278000.0; the TTM figure through Mar 2026 stood at $879000.0 (up 4783.33% YoY), while the FY2025 annual figure was $601000.0, changed N/A from the prior year.
  • Amortization of Deferred Charges was $278000.0 for Q1 2026 at Cogent Biosciences, up from $238000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $300000.0 in Q3 2025 to a low of $63000.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn -
7 Psyence Biomedical 227.32 Bn 227.31 Bn -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn
9 Abivax 91.71 Bn 91.71 Bn -
10 Cogent Biosciences 5.09 Bn 4.22 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 278,000.00
Mar 31, 2026 278,000.00
Dec 31, 2025 238,000.00
Dec 31, 2025 238,000.00
Sep 30, 2025 300,000.00
Sep 30, 2025 300,000.00
Jun 30, 2025 63,000.00
Jun 30, 2025 63,000.00
Dec 31, 2018 7,000.00
Dec 31, 2018 7,000.00
Sep 30, 2018 5,000.00
Sep 30, 2018 5,000.00
Jun 30, 2018 6,000.00
Jun 30, 2018 6,000.00
Mar 31, 2018 5,000.00
Mar 31, 2018 5,000.00
Dec 31, 2017 6,000.00
Dec 31, 2017 6,000.00
Sep 30, 2017 5,000.00
Sep 30, 2017 5,000.00